Calumet, Inc. (NASDAQ:CLMT – Get Free Report) has earned a consensus recommendation of “Hold” from the seven analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $51.75.
Several research firms have recently weighed in on CLMT. HC Wainwright raised their price objective on shares of Calumet from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Calumet in a research report on Friday, August 7th. Citigroup reissued a “buy” rating on shares of Calumet in a research note on Monday, August 10th. TD Cowen raised their price target on Calumet from $34.00 to $40.00 and gave the company a “hold” rating in a research report on Wednesday, August 12th. Finally, The Goldman Sachs Group lifted their price target on Calumet from $40.00 to $45.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th.
Check Out Our Latest Stock Report on CLMT
Insider Buying and Selling at Calumet
Institutional Investors Weigh In On Calumet
A number of hedge funds have recently made changes to their positions in CLMT. Islay Capital Management LLC bought a new position in shares of Calumet during the 4th quarter valued at $25,000. Aster Capital Management DIFC Ltd lifted its stake in Calumet by 294.7% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 1,646 shares of the oil and gas company’s stock worth $33,000 after purchasing an additional 1,229 shares during the last quarter. Global Retirement Partners LLC purchased a new stake in Calumet during the fourth quarter valued at about $34,000. Covestor Ltd boosted its position in Calumet by 29.1% during the fourth quarter. Covestor Ltd now owns 2,180 shares of the oil and gas company’s stock valued at $43,000 after buying an additional 492 shares during the period. Finally, Nykredit A S bought a new position in shares of Calumet during the second quarter valued at about $57,000. 34.41% of the stock is currently owned by institutional investors.
Calumet News Summary
Here are the key news stories impacting Calumet this week:
- Positive Sentiment: HC Wainwright raised its earnings forecasts and maintained a Buy rating. The firm increased its Q3 2026 EPS estimate to $0.62 from $0.60, Q4 to $0.24 from $0.22, FY2026 to $0.17 from $0.12, and FY2027 to $1.11 from $0.59. Its $75 price target implies substantial upside from the stock’s recent trading level. HC Wainwright earnings estimate report
- Positive Sentiment: The upward revisions suggest HC Wainwright expects stronger profitability over the next several quarters, potentially reflecting improved operating performance or business conditions. The revised FY2027 forecast is notably above the broader current-year consensus estimate of $0.46 per share. Calumet stock price expected to rise
- Neutral Sentiment: Calumet announced plans to attend the H.C. Wainwright conference. The event could provide investors with updates on strategy and operations, but no new financial information was disclosed in the announcement. Calumet conference announcement
- Neutral Sentiment: A Zacks analysis compared Calumet’s year-to-date performance with TXO Partners and the broader oil-and-energy sector. The article provides relative-performance context but does not indicate a new company-specific catalyst. Zacks Calumet sector performance analysis
- Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Calumet investors. Although the announcement does not establish wrongdoing, the prospect of litigation or regulatory concerns may weigh on sentiment and introduce uncertainty. Pomerantz investor investigation
Calumet Stock Down 0.7%
Shares of NASDAQ:CLMT opened at $53.13 on Wednesday. The firm has a market capitalization of $4.67 billion, a PE ratio of -34.28 and a beta of 0.72. The company has a 50-day moving average price of $43.76 and a two-hundred day moving average price of $36.21. Calumet has a twelve month low of $16.75 and a twelve month high of $54.69.
Calumet (NASDAQ:CLMT – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The oil and gas company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($1.16). The company had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the firm posted ($1.70) EPS. The business’s revenue for the quarter was up 40.8% compared to the same quarter last year. Analysts anticipate that Calumet will post 0.48 earnings per share for the current fiscal year.
About Calumet
Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) is an independent provider of high-value, essential product solutions derived from both petroleum and renewable feedstocks. The company operates an integrated network of manufacturing plants, blending terminals and storage facilities across North America, delivering customized products and technical services to industrial, automotive, consumer and agricultural end markets. By leveraging its scale and technical expertise, Calumet tailors supply chain and formulation solutions to meet stringent regulatory and performance requirements.
Calumet’s product portfolio includes specialty lubricants and base oils for high-performance applications; process oils and waxes for food-grade, cosmetic and packaging uses; industrial solvents and cleaning solutions; and fuel additives designed to optimize engine performance and emissions.
See Also
- Five stocks we like better than Calumet
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Calumet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calumet and related companies with MarketBeat.com's FREE daily email newsletter.
